Top line decelerating.
+12.4% YoY versus +16.2% prior. 3y CAGR +13.4%.
+12.4%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $94.2B
Fundamentals as of 2026-03-31
The Question
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
Bottom line: MCK is flagged as overvalued by the 1 legendary model, but earns a D sector grade (41/100) in Healthcare. Use the per-tab analysis to form your own view. Drill into the valuation breakdown and sector ranking for the full picture.
Mixed — McKesson Corporation has 68.8% ROE but D/E 10.90.
Financial story
Mixed — McKesson Corporation's 68.8% ROE is strong, but its 10.90 debt-to-equity is elevated.
0 of 6 legendary investor models rate MCK a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
McKesson Corporation's fair value depends on which model you trust. See the per-investor fair-value table in the valuation tab.
MCK trades at 19.1x earnings. Sector context and per-investor signals are in the valuation tab.
MCK and CVS differ on P/E, ROE, and revenue growth. See the full MCK vs CVS compare matrix.
Lynch evaluates MCK against his respective frameworks. Per-model fair value and reasoning are in the valuation tab.
MCK's P/E ratio is 19.1x. 5-year P/E history is in the financials tab.
How does MCK compare?
See exactly where MCK ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingMCK sits at #85 in Healthcare with a D grade (41/100).